Sickle cell disease patients are common "customers" of transfusion medicine service including simple transfusion needs, allo antibodies identification and recently with the introduction of BMT as a therapeutic option for SCD — the support of blood products after transplantation (including ABO mismatch transplants). The session will cover new advance therapies for patients with SCD from the prospective interest of the transfusion service. It will include all current new modalities of treatment available: Transfusion medicine specialist who will cover all new "alternatives" to transfusion such as Hydroxyurea and advances in iron chelating therapy. A pediatric apheresis expert will review relevant issues in RBC exchange for SCD including comparison to simple transfusion as per the recent evidence based medicine and finally, bone marrow transplanter will review the indications for BMT in SCD, and review the outcome of this new modality.